PHENOTYPE-GENOTYPE CORRELATIONS AND PERSONALIZED MEDICINE IN ATOPIC DERMATITIS

In addition to this symposium, the IEC is providing the Roadmap for Atopic Dermatitis at IID 2018. This downloadable PDF helps you make the most of IID 2018 by highlighting the symposia, posters, and e-poster sessions that focus on atopic dermatitis!

PROGRAM CHAIRS

• Emma Guttman-Yassky, New York, NY, US
• Stephan Weidinger, Kiel, Germany

• Role of genetic mechanisms in atopic dermatitis
• Linking genes and immune activation in atopic dermatitis
• The link between the barrier and immune dysregulations in atopic dermatitis
• Relevance of atopic dermatitis phenotypes to ongoing therapeutic development
• Future developments of personalized treatment approaches for our atopic dermatitis patients.

12:00 – 12:05 pm Welcome and Overview Emma Guttman-Yassky New York, NY

12:05 – 12:30 pm Genetic mechanisms of skin barrier failure in AD Wilson Liao San Francisco, CA

12:35 – 1:00 pm Genetic mechanisms in AD Stephan Weidinger Kiel, Germany

1:05 – 1:30 pm Skin barrier, immune dysregulation and itch – therapeutic implications Kenji Kabashima Kyoto, Japan

1:35 – 2:00 pm Differences in immune dysregulation in various AD phenotypes and the road to personalized medicine Emma Guttman-Yassky New York, NY

2:00 – 2:15 pm Q and A with plenary speakers

2:15– 2:55 pm Abstract Presentations

• # 555 - Integrating serum and skin biomarkers to assess disease extent beyond clinical scores, advancing precision therapeutics. Kunal Malik et al., Mount Sinai, New York, NY
• #559 - ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients. Emma Guttman et al., Mount Sinai, New York NY
• #1446 - Atopic Cytokines IL4/13 Perturb iPSC-Derived Itch-Specific Sensory Neurons. Zongyou Guo et al., Columbia University, New York, NY
• #1039 - Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy. John Common et al., A*STAR, Singapore